Navigation Links
Progress toward an alternative for EPO: Gas6 offers remedy where EPO fails today
Date:1/31/2008

Leuven, Belgium − Many patients with a chronic disease or cancer have to contend with anemia − and the severe fatigue that accompanies anemia impedes the patient considerably in his or her daily activities. At present, the hormone EPO is administered to a large number of these patients to alleviate the anemia. But unfortunately, treatment with EPO is not always effective, and not all patients respond to this therapy. VIB scientists connected to the Katholieke Universiteit Leuven have been researching the role of the Gas6 protein. This substance has proven successful in the treatment of mice with anemia, without causing the side effects that the use of EPO entails. In addition, Gas6 contributes to a reinforcement of EPOs effect. Gas6 might possibly form the basis for a new treatment for anemia and offer a remedy for patients where EPO is ineffective.

What is anemia?

When the blood contains too few red blood cells, or when the red blood cells contain too little hemoglobin, the condition is called anemia. Hemoglobin binds to oxygen from the lungs and conveys it throughout our bodies, where it plays an essential role in the bodys production of energy. If there are not enough red blood cells in our body, or if the red blood cells do not contain enough hemoglobin, then insufficient oxygen is transported. A shortage of oxygen in our tissues can cause people to feel tired and weak, and serious cardiovascular, neurological and musculoskeletal abnormalities develop.

EPO as the remedy

EPO (or Erythropoietin) is a hormone that is produced predominantly in the kidneys and that stimulates the formation of red blood cells. However, sometimes the kidneys do not produce enough EPO and anemia results. Such a shortage of EPO often occurs in patients with a chronic disorder (like kidney failure or rheumatoid arthritis) and in cancer patients. In the case of cancer, anemia can be caused by the disease itself as well as b
'/>"/>

Contact: Ann Van Gysel
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New MRI finding sheds light on multiple sclerosis disease progressio
2. Brain Lesions Predict MS Progression
3. Pregnancy may slow -- not accelerate -- progression to AIDS
4. STAAR Surgical Reports Operational Progress
5. Progression of SIV infection in monkeys raises
6. Study makes progress in zoning in on biomarkers for better colon cancer treatment
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. Limiting refined carbohydrates may stall AMD progression
9. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
10. New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
11. Study finds genetic influence on pace of HIV/AIDS progression
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 2ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference 3Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3The American Society of Transplantation Announces Dr Joren C Madsen as President 49219 1The American Society of Transplantation Announces Dr Joren C Madsen as President 49219 2BenefitMall Hosts New World of Healthcare Forum to Empower Partners to Find Solutions for Volatile Healthcare Industry 49218 1BenefitMall Hosts New World of Healthcare Forum to Empower Partners to Find Solutions for Volatile Healthcare Industry 49218 2BenefitMall Hosts New World of Healthcare Forum to Empower Partners to Find Solutions for Volatile Healthcare Industry 49218 3John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 1John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 2John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 3John Hancock Announces Enhancements to Group Long Term Care 28LTC 29 Insurance Products and Discount Program 49216 4